Table 2.
Summary of studies comparing isotonic saline to balanced crystalloid solutions
Study | Design | Population | Solutions | Outcome |
McFarlane et al[59] | RCT | Elective hepatobiliary/pancreatic surgery | 0.9% saline vs PL-148 | Iatrogenic metabolic acidosis with 0.9% saline |
Wilkes et al[47] | RCT | Major abdominal surgery | 0.9% saline vs Hartmann's (in HES) | Iatrogenic metabolic acidosis with 0.9% saline |
O'Malley et al[48] | RCT | Kidney transplant recipients | 0.9% saline vs RL | Iatrogenic metabolic acidosis and hyperkalemia with 0.9% saline |
Yunos et al[56] | Prospective before-and-after | Critically ill patients | Chloride-rich vs chloride-poor fluid strategy | More acidosis with chloride-rich; more alkalosis and reduced cost with chloride-poor |
Chowdbury et al[26] | RCT (cross-over) | Healthy volunteers | 0.9% saline vs PL-148 (2 L infusion) | ↑ Δ [Cl-]; ↑ Strong ion difference; ↓ RBF; ↑ weight gain; ↑ extravascular volume; ↑ time to micturation |
Chua et al[49] | Retrospective | Critically ill with DKA | 0.9% saline vs PL-148 | More rapid resolution of acidosis with PL-148 |
Shaw et al[55] | Retrospective | Major abdominal surgery | 0.9% saline vs PL-148 | ↑ Major infection; ↑ composite of complications; ↑ blood transfusions; and ↑ RRT with 0.9% saline |
Yunos et al[57] | Prospective before-and-after | Critically ill patients | Chloride-rich vs chloride-poor fluid strategy | ↑ AKI (KDIGO stage II/III); ↑ RRT with chloride-rich strategy |
Adapted from Raghunathan et al[58]. RCT: Randomized clinical trial; 0.9% saline: Normal saline; PL: Plasmalyte; RL: Ringers lactate; RBF: Renal blood flow; DKA: Diabetic ketoacidosis; AKI: Acute kidney injury; HES: Hydroxyethyl starch; RRT: Renal replacement therapy; KDIGO: Kidney disease improving global outcomes; FO: Fluid overload; FB: Fluid balance.